Xencor, Inc. (XNCR)
Nasdaq · Healthcare · Biotechnology
$25.63+3.18%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.9B
- 52-week range
- $10.38 – $30.61
- 52-week change
- +110.69%
- EPS (trailing)
- −$2.23
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $126M (+13.66%)
- Net income
- −$91.9M
- Operating margin
- −141.3%
- Diluted EPS
- −$1.24
- Free cash flow
- −$138M
From the company’s annual report on SEC EDGAR.
About Xencor, Inc.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies.
Headquarters: Pasadena, United States · 260 employees · xencor.com